The AIM-listed drug development company, ImmuPharma Plc, has raised £1.5 million, net of expenses, in a share placement with institutional investors that will enable it to finance early clinical development of its candidate cancer drug, IPP-204106.
The AIM-listed drug development company, ImmuPharma Plc, has raised £1.5 million, net of expenses, in a share placement with institutional investors that will enable it to finance early clinical development of its candidate cancer drug, IPP-204106.